目的 探讨咳喘宁胶囊联合孟鲁司特钠和布地奈德治疗儿童咳嗽变异性哮喘的临床疗效。方法 选取2015年1月-2016年1月在子长县人民医院接受治疗的儿童咳嗽变异性哮喘患儿86例，随机分为对照组和治疗组，每组各43例。对照组吸入布地奈德粉吸入剂，1 g/次，1次/8 h；且睡前口服孟鲁司特钠咀嚼片，年龄>5岁：5 mg/次，年龄≤5岁：4 mg/次，1次/d。治疗组在对照组基础上口服咳喘宁胶囊，4粒/次，3次/d。两组患儿均治疗8周。观察两组的临床疗效，比较两组咳嗽评分、肺功能和血清炎性因子的情况。结果 治疗后，对照组和治疗组的总有效率分别为81.40%、95.35%，两组比较差异有统计学意义（P<0.05）。治疗后，两组咳嗽评分显著下降，而第一秒用力呼气容积（FEV1）、用力肺活量（FVC）、最大呼气流量（PEF）和FEV₁/FVC均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组免疫球蛋白E（IgE）、肿瘤坏死因子α（TNF-α）和白细胞介素-8（IL-8）水平均明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的降低程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 咳喘宁胶囊联合孟鲁司特钠和布地奈德治疗儿童咳嗽变异性哮喘具有较好的临床疗效，可改善临床症状和肺功能，降低炎症因子水平，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Kechuanning Capsules combined with montelukast sodium and budesonide in treatment of children with cough variant asthma. Methods Children (86 cases) with cough variant asthma in Zichang County People's Hospital from January 2015 to January 2016 were randomly divided into the control and treatment groups, and each group had 43 cases. Children in the control group were inhalation administered with Budesonide Powder for inhalation, 1 g/time, once every 8 h. Children in the control group were also po administered with Montelukast Sodium Chewable Tablets before bedtime, Age>5 years:5 mg/time, Age≤5 years:4 mg/time, once daily. Children in the treatment group were po administered with Kechuanning Capsules on the basis of the control group, 4 grains/time, three times daily. Children in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and cough scores, lung function, and serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.40% and 95.35%, respectively, and there was difference between two groups (P<0.05). After treatment, the cough scores in two groups were significantly decreased, but FEV1, FVC, PEF, and FEV₁/FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, IgE, TNF-α, and IL-8 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Kechuanning Capsules combined with montelukast sodium and budesonide has clinical curative effect in treatment of children with cough variant asthma, and can improve clinical symptoms and lung function, reduce the level of inflammatory factors, which has a certain clinical application value.